GTBP GT Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 109657 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-309.0%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,446.5%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets—
Debt / equity0.00x
Current ratio4.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $3.47M | $5.80M | $6.47M | $8.81M | $9.59M |
| SG&A expense | $8.95M | $8.57M | $7.11M | $12.45M | $47.92M |
| Operating income | -$12.42M | -$14.36M | -$13.58M | -$21.26M | -$57.52M |
| Interest expense | $127,000 | — | $213,000 | $8,000 | $718,000 |
| Net income | -$28.35M | -$13.16M | -$7.60M | -$20.88M | -$58.01M |
| EPS (basic) | -6.68 | -6.94 | -5.64 | -19.66 | -2.06 |
| EPS (diluted) | -6.68 | -6.94 | -5.64 | -19.66 | -2.06 |
| Weighted avg. shares (diluted) | 5.51M | 1.90M | 1.35M | 1.06M | 28.16M |
| Balance sheet | |||||
| Cash & equivalents | $6.81M | $4.04M | $1.08M | $5.67M | $8.97M |
| Short-term investments | — | — | $12.89M | $10.84M | $23.01M |
| Current assets | $8.11M | $4.23M | $14.06M | $16.56M | $32.17M |
| Total assets | $8.11M | $4.23M | $14.11M | $16.74M | $32.17M |
| Current liabilities | $2.32M | $5.90M | $6.63M | $4.94M | $10.26M |
| Total liabilities | $2.32M | $5.90M | $6.63M | $5.00M | $10.26M |
| Shareholders' equity | $5.79M | -$1.67M | $7.48M | $11.73M | $21.91M |
| Shares outstanding | 1.02M | 2.23M | 1.38M | 1.09M | 32.06M |
| Cash flow statement | |||||
| Operating cash flow | -$12.91M | -$12.90M | -$8.85M | -$15.22M | -$15.61M |
| Investing cash flow | — | $12.89M | -$2.01M | $12.14M | -$23.04M |
| Financing cash flow | $15.78M | $2.98M | $6.27M | -$224,000 | $42.32M |
| Stock-based compensation | $432,000 | $230,000 | — | $7.70M | $33.90M |
| Dividends paid | $229,000 | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.